COMPANY

Altesa BioSciences

HQ: College Park, GA source · altesabio.com ↗ · Southeast

Keywords: respiratory chronic obstructive pulmonary disease Rhinovirus Infection Respiratory Disease Copd Lower Respiratory Disease COPD Exacerbation Acute COPD With Acute Lower Respiratory Infection Rhinovirus Virus Diseases RNA Virus Infection Enterovirus Enterovirus Infections Infection Viral Respiratory Complication Respiratory Tract Infections Respiratory Tract Diseases Respiratory Viral Infection Upper Resp Tract Infection Upper Respiratory Tract Infections Upper Respiratory Disease Upper Respiratory Disorder Acute Upper Respiratory Disease Upper Respiratory Infection Viral Respiratory Infections Viral Infection Emphysema or COPD Lower Respiratory Disorder Lower Respiratory Tract and Lung Infections Respiratory Disease Chronic Lung Diseases Lung Disease Chronic Chronic Lower Respiratory Diseases Chronic Respiratory Disease Vapendavir

Location: College Park, GA · source · Oct 15, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $75M (Form D filed Feb 23, 2026). SEC Form D 0001960618-26-000003 (Feb 23, 2026)
Evidence (1 event)
- Feb 23, 2026 · SEC Form D 0001960618-26-000003
  Name of Issuer: Altesa BioSciences, Inc.; CIK: 1960618; Address: College Park, GA; Submission type: D; Filing date: 2026-02-23; Industry Group: Pharmaceuticals; Date of First Sale: 2026-02-13; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 74999986; Total Amount Sold: 74999986; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

May 1, 2026 Trial start Phase 2: Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD source ↗
Mar 12, 2025 Trial start Phase 1/Phase 2: A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir source ↗
Nov 20, 2023 Trial start Phase 2: RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection source ↗
May 19, 2023 Trial start 1: Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD source ↗

Upcoming milestones

Nov 15, 2027 (ESTIMATED) · Phase 2 · Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD · NCT07610395

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07610395	Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD	Phase 2	Recruiting	May 1, 2026	Nov 15, 2027 (estimated)
NCT06149494	RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection	Phase 2	Completed	Nov 20, 2023	Mar 30, 2025 (actual)
NCT06834295	A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir	Phase 1/Phase 2	Completed	Mar 12, 2025	Mar 23, 2025 (actual)
NCT05962645	Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD	1	Completed	May 19, 2023	Dec 12, 2023 (actual)